A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in XXXX : Possible stage-specific effects.

@entity1 @entity161 @entity716 @entity9539
BACKGROUND: @entity9539 have shown promise as an adjunctive treatment for @entity161 . However, efficacy across studies has been inconsistent. We conducted a meta-analysis of published controlled studies with the goal of detecting different efficacy profiles at various stages of @entity161 . METHODS: An online search was conducted for randomized, double-blind, placebo-controlled clinical trials, and a meta-analysis was conducted. RESULTS: Ten studies met the criteria for inclusion. Among @entity1 in the prodromal phase of @entity161 , omega-3 supplementation reduced psychotic symptom severity and lowered conversion rates to first-episode @entity716 . In @entity1 with first-episode @entity161 , omega-3 decreased nonpsychotic symptoms, required lower antipsychotic medication dosages, and improved early treatment response rates. Omega-3 had mixed results in @entity1 with stable chronic @entity161 , with only some @entity1 experiencing significant benefits. Among @entity1 with chronic @entity161 , use of @entity9539 both by those experiencing acute exacerbations and those who had discontinued antipsychotic medications resulted in worsening of @entity716 . CONCLUSIONS: The data suggest that @entity9539 may be efficacious in reducing clinical symptoms for @entity1 in the earlier stages of @entity161 (prodrome and first episode), while producing mixed results for @entity1 in the chronic stages. Based on these results, @entity9539 would not be recommended for acute exacerbations in @entity1 with chronic @entity161 nor for relapse prevention after discontinuation of antipsychotics.
